NVP, Replacement Therapy for Nicotine Addiction in Malaysia

Innovation by 2FIRSTS.ai
May.24.2024
NVP, Replacement Therapy for Nicotine Addiction in Malaysia
Despite awareness of smoking's harm, nicotine addiction persists, leading to innovative methods like NVP for successful quit smoking.

According to Malaysian media kosmo's report on May 23rd, while most people are aware of the health risks of smoking, there are still individuals who are unable to quit due to nicotine addiction. Professor Madya Dr. Rusdi Abd. Rashid from the Malaysia University Addiction Science Research Center pointed out that nicotine is not only found in traditional cigarettes but also in e-cigarettes. Additionally, while the number of traditional cigarette smokers is decreasing, the use of e-cigarettes is on the rise. He also mentioned that some people who have never smoked before have developed a smoking habit due to the influence of e-cigarettes.

 

The number of e-cigarette users is on the rise. However, many smokers actually want to quit but have not been successful. Dr. Lucidi explains that once people become addicted to nicotine, it is difficult to quit smoking. Therefore, they need help from medications and counseling.

 

He said, "If smokers follow the correct process, they may be able to quit smoking completely within a month. From a treatment perspective, we have nicotine replacement therapy available, along with counseling sessions.

 

Meanwhile, Lumelife Sdn Bhd's latest approach is to utilize NVP, a form of nicotine replacement therapy resembling a vaporizer. In Australia, NVP has been widely used to assist patients with nicotine addiction. Dr. Lucidi explains that NVP is a safe product for individuals looking to quit smoking.

 

He said, "I understand that this device is made from a concentration of nicotine and it can help us assist those who want to quit smoking. However, before using NVP, patients need to go see a doctor and get a prescription from the doctor, they cannot use it casually.

 

The product has been registered, but has not yet been launched in order to increase knowledge and training for doctors in advance. Recently, Lumelife has partnered with UMCAS and the Malaysian Islamic Doctors Organization (PERDIM) to enhance medical knowledge and training regarding NVP prescriptions within the MAF framework, equipping healthcare professionals with the knowledge and skills needed to handle complex emergency situations related to nicotine dependence.

 

He said that Lumelife will leverage its expertise in the field of medical education to focus on nicotine dependency management under the MAF. 

 

He said, "Through this collaboration, we have jointly developed a comprehensive training program specifically for nicotine dependency management. This program will cover various topics, including the physiological and psychological effects of nicotine, cognitive aspects of addiction, identifying and distinguishing diseases related to vaping, and strategies for smoking cessation using TGA-approved NVP.

 

Health professionals will have the opportunity to deepen their understanding of health issues related to vaping and enhance their clinical skills in addressing this challenge through lectures, workshops, and clinical sessions. Professor Pan Shidi stated that individuals addicted to nicotine need the help of medication and counseling in order to successfully quit smoking. He mentioned that if smokers fairly go through the process of dependence, they may be able to quit smoking within a month. In terms of treatment options, experts are currently using nicotine replacement therapy and conducting one-on-one counseling sessions.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Italy Fines PMI €7 Million Over Misleading ‘Smoke-Free Future’ Marketing Claims
Italy Fines PMI €7 Million Over Misleading ‘Smoke-Free Future’ Marketing Claims
Italy’s Competition and Market Authority (AGCM) has fined Philip Morris Italia €7 million, finding that the company’s use of “smoke-free future” and related claims in promoting products such as IQOS, VEEV and ZYN could mislead consumers.
Jun.16
U.S. FDA: Youth E-Cigarette Prevention Campaign Prevented About 444,000 Initiations and Reduced Illegal Vape Sales
U.S. FDA: Youth E-Cigarette Prevention Campaign Prevented About 444,000 Initiations and Reduced Illegal Vape Sales
The U.S. Food and Drug Administration (FDA) said its youth e-cigarette prevention campaign, “The Real Cost,” prevented about 444,000 U.S. youth from starting e-cigarette use between 2023 and 2024 and blocked more than $42 million in unauthorized e-cigarette sales that would have been used by youth.
Market
Jun.25
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
British American Tobacco (BAT) shares rose sharply on May 12 after the U.S. Food and Drug Administration signaled it would deprioritize enforcement against certain unauthorized e-cigarette and nicotine pouch products with accepted premarket applications. Investors viewed the move as favoring established players such as BAT’s Vuse and Velo brands.
BAT
May.13
U.S. Convenience Stores Rebalance Backbar as Nicotine Pouches Outpace Cigarettes
U.S. Convenience Stores Rebalance Backbar as Nicotine Pouches Outpace Cigarettes
As cigarette volumes continue to decline, U.S. convenience-store operators are reconfiguring backbar space to accommodate modern oral nicotine products such as nicotine pouches. Industry data show nicotine pouches have become one of the fastest-growing nicotine categories while generating higher margins for retailers.
Jun.12
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japanese Tobacco (JT) reports Q1 2026 revenue of 924 billion yen, a 15.2% increase; operating profit rises 24.7%.
May.08 by 2FIRSTS.ai
Opinion | As EU Reviews Tobacco Rules, Experts Warn Against Overlooking Smokers’ Alternatives
Opinion | As EU Reviews Tobacco Rules, Experts Warn Against Overlooking Smokers’ Alternatives
As the European Commission reviews its tobacco and advertising rules, two experts who provided written comments to 2Firsts argue that future EU policy should not overlook adult smokers’ alternatives. Dr Garrett McGovern and Dr Carmen Escrig say regulators should weigh relative risk, adult switching, flavours, consumer behaviour and scientific uncertainty alongside youth protection.
Industry Insight
Jun.01